Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2017-11-13 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 3B - Grant of Employee Peformance Rights 10 pages 78.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. The content details the issuance of unlisted employee options (Performance Rights), terms of the securities, number of securities, and application for quotation on ASX. It includes no financial statements or detailed financial performance data, nor is it a report or presentation. It is clearly an announcement regarding capital changes, specifically new share issues and securities quotation. Therefore, the document fits the category of Share Issue/Capital Change announcements.
2017-11-13 English
Chairman's Address to Shareholders 2 pages 101.2KB
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting 13 November 2017 Sydney Chairman’s Address by Malcolm J McComas' and contains a speech given at the AGM. It discusses company performance, financial highlights, and board member introductions, typical of AGM presentations. There is no detailed financial report or comprehensive data, but rather a chairman's address at the AGM. Therefore, this document fits the category of AGM Information (AGM-R). The document length is 4708 characters, consistent with a presentation or speech rather than a full annual report or financial filing.
2017-11-12 English
CEO Presentation to 2017 AGM 27 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by the CEO of Pharmaxis, covering the company's overview, drug development pipeline, management team, strategic partnerships, and future outlook. It includes forward-looking statements, descriptions of drug candidates, clinical trial phases, and business milestones. The content is structured as a presentation aimed at investors or stakeholders, focusing on company strategy, product pipeline, and financial potential rather than providing formal financial statements or regulatory disclosures. There is no indication that this is an official annual or quarterly report, audit report, earnings release, or regulatory filing. The presence of slides, forward-looking statements, and detailed business and financial strategy points strongly suggest this is an Investor Presentation (IP). The document length and detail also support this classification rather than a brief announcement or summary.
2017-11-12 English
Appendix 4C - quarterly 5 pages 126.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the quarter ended 30 September 2017. It includes operating, investing, and financing cash flows, reconciliation of cash and cash equivalents, payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The document is 8313 characters long, which is substantial and contains actual financial data and analysis for a quarterly period. The presence of detailed financial statements and notes aligns with the definition of an Interim / Quarterly Report (IR). It is not a brief announcement or a certification letter, nor is it a full annual report or other filing types. Therefore, the correct classification is IR (Interim / Quarterly Report). Q1 2017
2017-10-26 English
Quarterly Shareholder Update - September 2017 7 pages 362.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – September 2017' and contains detailed information about the company's drug discovery progress, clinical trials, partnerships, and financial metrics for the quarter ended 30 September 2017. It includes substantive financial data such as revenue, expenses, and net profit/loss for the quarter, as well as operational updates and strategic developments. The presence of actual financial statements and analysis for a period shorter than a full fiscal year indicates this is a comprehensive interim or quarterly report. It is not merely an announcement or a brief summary, nor is it a transcript, proxy, or regulatory filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2017
2017-10-26 English
Investor Presentation - 23 October 2017 33 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation focusing on Pharmaxis' business overview, drug development pipeline, financial highlights, management team, and strategic partnerships. It includes forward-looking statements, product development stages, milestone payments, and market focus areas. The content is typical of an investor presentation aimed at providing comprehensive information about the company's strategy, financial position, and future prospects to investors. There is no indication that this is a formal annual report, earnings release, or regulatory filing. The length and detail support it being a presentation rather than a brief factsheet or announcement. Therefore, the document best fits the category of an Investor Presentation (IP).
2017-10-22 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.